Elevance Health, Inc. (ELV) Valuation
Historical valuation analysis based on 1081 data points (2022-06-28 to 2026-10-16)
Elevance Health remains one of the leading health insurers in the US, providing medical benefits to 45 million medical members at the end of 2025. The company offers employer, individual, and gover...
Elevance Health, Inc. (ELV) currently trades at a P/E ratio of 18.71 (historical range: 11.49–22.83, median: 17.83), placing it at the 63th percentile — above its historical average, P/S ratio of 0.46 (range: 0.32–0.91, 30th percentile — below its historical average), EV/EBITDA of 13.44 (range: 8.22–17.30, 64th percentile).
Over the historical period (2022-06-28 to 2026-10-16), Elevance Health, Inc.'s P/E ratio has contracted by 20% over the observed period (from an average of 19.3 to 15.5).
Elevance Health, Inc. trades near its historical valuation range, with most metrics close to their median levels.
Historical Valuation Metrics
| Metric | Current | Median | %ile | Assessment |
|---|---|---|---|---|
| P/E Ratio | 18.71 | 17.83 | 63th | above its historical average |
| P/S Ratio | 0.46 | 0.65 | 30th | below its historical average |
| EV/EBITDA | 13.44 | 12.92 | 64th | above its historical average |
| FCF Yield | 6.77% | 6.93% | 45th | near its historical average |
Elevance Health, Inc. (ELV) Valuation & P/E History
Elevance Health, Inc. (ELV) is a US-listed stock operating in the Healthcare sector, specifically the Healthcare Plans industry currently trading at $426.44 with a market capitalization of $92.5 billion. This page provides historical valuation analysis for ELV based on 1081 data points covering 2022-06-28 to 2026-10-16. The P/E ratio of 18.71 is above the historical median of 17.83, placing ELV at the 63th percentile of its valuation range. The P/S ratio of 0.46 compares to a median of 0.65.
ELV Valuation Metrics & Historical Range
The valuation table above shows Elevance Health, Inc.'s current and historical valuation multiples, including P/E ratio, P/S ratio, EV/EBITDA, FCF yield, and dividend yield. Each metric is compared to its own historical range to determine whether ELV is currently trading above or below its typical valuation levels.
- P/E ratio: Price-to-earnings measures how much investors pay per dollar of earnings. A P/E above the historical median suggests ELV is expensively valued; below the median suggests it is cheap.
- P/S ratio: Price-to-sales is useful for companies with volatile or negative earnings. Lower P/S relative to history may indicate value.
- EV/EBITDA: Enterprise value to EBITDA adjusts for debt and cash, providing a capital-structure-neutral valuation measure for Elevance Health, Inc..
- FCF yield: Free cash flow yield shows the cash return relative to market price. Higher yields may indicate undervaluation.
Is ELV Overvalued or Undervalued?
Elevance Health, Inc. trades near its historical valuation range, with most metrics close to their median levels. The overall valuation percentile of 52 combines P/E, P/S, and EV/EBITDA percentiles into a single measure of how expensive ELV is relative to its own history. A percentile below 25 suggests the stock may be undervalued, while a percentile above 75 suggests it may be overvalued.
However, valuation is only one factor in investment decisions. A stock can remain "overvalued" for years if growth accelerates, or "undervalued" if the business deteriorates. Always combine valuation analysis with financial statement analysis and the full ELV analysis page for a complete picture.
Valuation data is computed from historical price and fundamental data via Polygon.io and Finnhub.ELV trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.